Aclarion, Inc. (ACON) |
|
0.83 0.005 (0.61%)
|
03-24 15:59 |
|
Open: |
0.8241 |
Pre. Close: |
0.825 |
|
High:
|
0.83 |
Low:
|
0.8003 |
|
Volume:
|
12,923 |
Market Cap:
|
7(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:23:45 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 1.1 One year: 1.29 |
| Support: |
Support1: 0.76 Support2: 0.64 |
| Resistance: |
Resistance1: 0.94 Resistance2: 1.1 |
| Pivot: |
0.73  |
| Moving Average: |
MA(5): 0.81 MA(20): 0.72
MA(100): 0.72  MA(250): 0 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 58 %D(3): 55.3 |
| RSI: |
RSI(14): 61.6 |
| 52-week: |
High: 4.05 Low: 0.37 |
| Average Vol(K): |
3-Month: 39 (K) 10-Days: 22 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ACON ] has closed below upper band by 13.4%. Bollinger Bands are 4.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.83 - 0.83 |
0.83 - 0.84 |
|
Low:
|
0.79 - 0.8 |
0.8 - 0.8 |
|
Close:
|
0.82 - 0.83 |
0.83 - 0.84 |
|
Company Description |
|
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California. |
Headline News |
Fri, 17 Mar 2023
Why Baidu Shares Are Trading Higher By More Than 6%? Here Are ... - Benzinga
Tue, 07 Mar 2023
Aclarion Announces Alpesh Patel MD MBA as a Key Opinion Leader ... - GlobeNewswire
Wed, 15 Feb 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace
Wed, 15 Feb 2023
Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium - Yahoo Finance
Mon, 06 Feb 2023
Why Omeros Are Trading Higher By 32%? Here Are Other Stocks ... - Benzinga
Tue, 31 Jan 2023
Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Health Information Services |
| Shares Out. |
0 (M) |
| Shares Float |
8 (M) |
|
% Held by Insiders
|
4.98e+006 (%) |
|
% Held by Institutions
|
33.9 (%) |
|
Shares Short
|
61 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-5.9e+006 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-10 |
|
Return on Assets (ttm)
|
89.5 |
|
Return on Equity (ttm)
|
-149.7 |
|
Qtrly Rev. Growth
|
60440 |
|
Gross Profit (p.s.)
|
-0.01 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-1.7 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-5 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
60310 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
